Informace o publikaci

Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis

Autoři

PETERKA Marek VALIS Martin SOUCEK Ondrej KREJSEK Jan SOBISEK Lukas SEJKOROVA Ilona KLIMOVA Blanka ŠTOURAČ Pavel PAVELEK Zbysek NOVOTNY Michal

Rok publikování 2023
Druh Článek v odborném periodiku
Časopis / Zdroj EUROPEAN NEUROLOGY
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate
Doi http://dx.doi.org/10.1159/000532022
Klíčová slova Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate
Popis Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info